Detection of pre-existing neutralizing antibodies against Ad26 in HIV-1-infected individuals not responding to the Ad26.COV2.S vaccine

[1]  K. Liang,et al.  Humoral immune response to inactivated COVID-19 vaccination at the 3rd month among people living with HIV , 2023, BMC Infectious Diseases.

[2]  C. Berking,et al.  Intensity and longevity of SARS-CoV-2 vaccination response in patients with immune-mediated inflammatory disease: a prospective cohort study , 2022, The Lancet Rheumatology.

[3]  H. Schuitemaker,et al.  Durable antibody responses elicited by 1 dose of Ad26.COV2.S and substantial increase after boosting: 2 randomized clinical trials , 2022, Vaccine.

[4]  Hengchun Li,et al.  Seroprevalence of neutralizing antibodies against adenovirus type 26 and 35 in healthy populations from Guangdong and Shandong provinces, China , 2022, Virologica Sinica.

[5]  D. Moodley,et al.  Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial , 2022, The Lancet HIV.

[6]  E. V. Tsyganova,et al.  Sputnik V protection from COVID-19 in people living with HIV under antiretroviral therapy , 2022, eClinicalMedicine.

[7]  A. Trkola,et al.  Antibody Response in Immunocompromised Patients After the Administration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine BNT162b2 or mRNA-1273: A Randomized Controlled Trial , 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  T. Harrer,et al.  Characterization of Serum and Mucosal SARS-CoV-2-Antibodies in HIV-1-Infected Subjects after BNT162b2 mRNA Vaccination or SARS-CoV-2 Infection , 2022, Viruses.

[9]  N. Klopp,et al.  Comparative Magnitude and Persistence of Humoral SARS-CoV-2 Vaccination Responses in the Adult Population in Germany , 2022, Frontiers in Immunology.

[10]  Maristela L Onozato,et al.  Comparative Immunogenicity and Effectiveness of mRNA-1273, BNT162b2, and Ad26.COV2.S COVID-19 Vaccines , 2021, The Journal of infectious diseases.

[11]  E. Wolf,et al.  Humoral response to SARS-CoV-2 vaccines in people living with HIV , 2021, Infection.

[12]  J. Montaner,et al.  Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy , 2021, medRxiv : the preprint server for health sciences.

[13]  J. Alcorn,et al.  Comparative analysis of human immune responses following SARS-CoV-2 vaccination with BNT162b2, mRNA-1273, or Ad26.COV2.S , 2021, npj Vaccines.

[14]  O. Laeyendecker,et al.  The BNT162b2 mRNA Vaccine Elicits Robust Humoral and Cellular Immune Responses in People Living With Human Immunodeficiency Virus (HIV) , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  P. Klenerman,et al.  Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial , 2021, The Lancet HIV.

[16]  E. Chu,et al.  Evaluation of the automated LIAISON® SARS-CoV-2 TrimericS IgG assay for the detection of circulating antibodies , 2021, Clinical chemistry and laboratory medicine.

[17]  Nguyen H. Tran,et al.  Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK , 2020, Lancet.

[18]  Qian Wang,et al.  Heat inactivation of serum interferes with the immunoanalysis of antibodies to SARS‐CoV‐2 , 2020, Journal of clinical laboratory analysis.

[19]  C. Bethel,et al.  Evaluation of the EUROIMMUN Anti-SARS-CoV-2 ELISA Assay for detection of IgA and IgG antibodies , 2020, bioRxiv.

[20]  S. Sirima,et al.  A review of 65 years of human adenovirus seroprevalence , 2019, Expert review of vaccines.

[21]  K. Bojang,et al.  A Novel Chimpanzee Adenovirus Vector with Low Human Seroprevalence: Improved Systems for Vector Derivation and Comparative Immunogenicity , 2012, PloS one.

[22]  K. Mansfield,et al.  International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. , 2011, Vaccine.

[23]  K. H. Hullsiek,et al.  Hepatitis B vaccine responses in a large U.S. military cohort of HIV-infected individuals: another benefit of HAART in those with preserved CD4 count. , 2009, Vaccine.

[24]  J. Kublin,et al.  Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  OUP accepted manuscript , 2022, The Journal of Infectious Diseases.